Disclaimer: The content below is intended solely for educational and research purposes. BPC-157 and TB-500 are research-use-only (RUO) compounds not approved by the FDA, EMA, or any major regulatory authority for human therapeutic use. Nothing here constitutes medical advice. Always consult a licensed healthcare professional before considering any peptide compound.
What Are BPC-157 and TB-500?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid sequence — originally isolated from a cytoprotective protein found in human gastric juice. It has been studied extensively in rodent models for its apparent roles in gastrointestinal protection, tendon and ligament repair, and angiogenesis.
TB-500 is a synthetic analogue of Thymosin Beta-4 (Tβ4), a naturally occurring protein encoded by the TMSB4X gene and found at high concentrations in platelets and wound fluid. Tβ4 plays a central role in actin regulation, cell migration, and tissue remodeling. TB-500 replicates the key active region of this protein.
Both compounds are classified as research-use-only materials. No controlled clinical trials in humans have validated their efficacy or established safe dosing ranges for therapeutic use.
Mechanisms of Action
How BPC-157 Works
Preclinical data suggests BPC-157 exerts effects through several molecular pathways:
- Nitric oxide (NO) system modulation: upregulates endothelial nitric oxide synthase (eNOS), promoting vasodilation and angiogenesis in injured tissue
- Growth factor receptor interaction: animal studies indicate interaction with VEGFR2 and EGF receptor signaling cascades
- Tendon fibroblast activation: rodent models show accelerated collagen synthesis in transected tendons (Sikiric et al., multiple publications)
- Gut mucosal cytoprotection: consistent with the protein's origin in gastric juice; studied in models of NSAID-induced and ethanol-induced ulceration
These effects are well-characterized in animal models. Human mechanistic data is essentially absent from peer-reviewed literature.
How TB-500 Works
TB-500's mechanism centers on its actin-sequestering domain (the LKKTET motif):
- Binds G-actin (globular actin), modulating the actin pool available for cytoskeletal remodeling and cell migration
- Promotes keratinocyte and endothelial cell migration — a prerequisite for wound closure
- Activates VEGF-driven angiogenesis, supporting neovascularization in ischemic tissue models
- In cardiac injury models, Thymosin Beta-4 has shown cardioprotective and progenitor-cell-recruiting effects (Bock-Marquette et al.)
Note: most human data comes from trials using Thymosin Alpha-1 or the native Tβ4 protein (RegeneRx trials), not TB-500 specifically. Extrapolation carries significant uncertainty.
Why Researchers Combine BPC-157 and TB-500
The combination is common in research settings because the two peptides are theorized to operate through complementary, non-overlapping pathways:
| Peptide | Primary Mechanism | Routes Used in Animal Studies |
|---|---|---|
| BPC-157 | NO system, VEGFR2, local fibroblast activation | SC, IM, oral (gavage in models) |
| TB-500 | Actin sequestration, systemic cell migration | SC, IV (in models) |
BPC-157 tends to be associated with localized, direct reparative signaling at the injury site, while TB-500's systemic actin-binding activity may support broader tissue reach and cell recruitment. Some rodent studies comparing single-compound versus combined protocols observe additive outcomes in soft-tissue injury models — but no controlled human trial has validated this theoretical synergy.
Important: the "stack" concept is largely extrapolated from anecdotal researcher accounts and animal data. Human pharmacokinetics, interaction profiles, and optimal ratios remain unstudied in peer-reviewed controlled trials.
Reconstitution — Standard Research Practices
Both BPC-157 and TB-500 are typically supplied as lyophilized (freeze-dried) powder. Proper reconstitution is essential for experimental reproducibility and compound integrity.
Principles consistently applied in published protocols:
- Solvent: Bacteriostatic water (containing 0.9% benzyl alcohol) for subcutaneous administration models; sterile water for in vitro or single-use preparations
- Technique: Inject solvent slowly down the inside wall of the vial — never directly onto the powder cake — to prevent foaming and peptide denaturation
- Agitation: Gentle swirling only; vortexing is avoided as mechanical shear can disrupt peptide tertiary structure
- Storage post-reconstitution: 2–8°C (standard refrigeration), away from light; most protocols specify use within 28–30 days. Repeated freeze-thaw cycles are avoided.
For precise volume-to-concentration calculations based on vial size and target research dose, the PeptideMed Dosage Calculator handles the arithmetic for common vial configurations and solvent volumes.
Dosing Ranges from Preclinical Literature
The ranges below are drawn from animal model studies only and must not be applied to human use without professional medical supervision.
BPC-157 (rodent data)
- Systemic (SC/IM): 10 µg/kg to 10 mg/kg bodyweight — the wide range reflects varying injury models and endpoints across studies
- Local injection at injury site: typically lower concentrations delivered directly to the target tissue
- Oral (gavage): some studies use microgram-range dosing; oral bioavailability in rodents appears preserved, unlike most peptides
TB-500 (rodent data)
- Systemic: 2–20 mg/kg across wound-healing and ischemia models
- Topical application: studied in corneal and dermal wound models
- RegeneRx's human trials with native Tβ4 used different formulations; TB-500 itself lacks equivalent human dosing data
Regulatory and Safety Context
Regulatory Status
- FDA (USA): Neither compound is approved as a drug. As of mid-2026, BPC-157's compounding status has undergone multiple regulatory changes: it was removed from the FDA 503A bulks list (Category 2, effectively banning pharmacy compounding) in September 2023; HHS Secretary Robert F. Kennedy Jr. then announced in February 2026 that BPC-157 would be reclassified back to Category 1, potentially restoring compounding pharmacy access with a physician's prescription — subject to a Pharmacy Compounding Advisory Committee (PCAC) review scheduled for July 2026, the outcome of which remains uncertain at time of publication. TB-500 has faced analogous compounding restrictions and reclassification proceedings. Outside of any physician-supervised compounding pathway (if and when fully restored), both compounds are legally sold only as research-use-only (RUO) materials for in-vitro or laboratory research and are not for human consumption.
- WADA (2026): Both compounds are prohibited under the 2026 WADA Prohibited List, banned both in and out of competition. BPC-157 is classified under S0 (Non-Approved Substances). TB-500 (Thymosin Beta-4 and its synthetic analogues) is prohibited under both S0 (Non-Approved Substances) and S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Both are additionally banned by the NCAA, NFL, NBA, NHL, and most major professional sports organizations. Detection windows for TB-500 are reported at 30–45 days post-use, with sanctions of 2–4 years for violations. Any competitive athlete subject to anti-doping testing faces significant risk from either compound.
- Brazil (ANVISA): Neither BPC-157 nor TB-500 is registered with ANVISA in any pharmaceutical category, including as compounded medications. ANVISA has explicitly stated that these peptides are not regularized for health use in Brazil in any form. Importation, commercial sale, or clinical use outside of a formally approved research protocol constitutes a violation of Brazilian health regulations. There is no current regulatory pathway toward approval for either compound in Brazil as of 2026.
Safety Signals from Available Data
BPC-157's preclinical toxicity profile in rodents is generally favorable — no LD50 has been established in standard acute toxicity studies, and chronic administration models have not shown organ toxicity signals. However, the absence of a toxicity signal in rodent models does not establish human safety. TB-500 has more indirect human exposure context via native Tβ4 trials, which reported generally mild adverse event profiles, but TB-500 itself has not undergone equivalent human safety assessment.
Related Peptides in the Research Catalog
Researchers working in tissue repair and recovery contexts often explore adjacent compounds. The PeptideMed catalog includes several peptides studied in overlapping biological contexts:
- CJC-1295 — GHRH analogue studied for growth hormone secretion; relevant to recovery and anabolic physiology research
- Ipamorelin — selective GH secretagogue with a favorable selectivity profile in rodent models; often studied alongside GHRH analogues
- GHK-Cu — copper-binding tripeptide studied for skin remodeling, wound healing, and anti-inflammatory effects in in vitro and animal models